Alibaba Health Information Technology Limited provided unaudited consolidated earnings guidance for the six months ended September 30, 2022. For the period, the Group expects to record a profit for the period of not less than RMB 80 million as compared with a loss for the period of approximately RMB 231.6 million for the corresponding period in 2021. The Board believes such turnaround from loss to profit is mainly attributable to, among other things: the continuous growth in the number of users on the Group's pharmaceutical direct sales business platforms; the operation refinement of the Group's business which has improved its bargaining and pricing power and enhanced its operational efficiency, and the improvement in efficiency and cost sharing driven by the platform economies of scale.